Opinion|Videos|December 4, 2024
Early Diagnosis
Key Takeaways
- Early diagnosis and treatment of FCS are vital to prevent severe complications like pancreatitis and enhance patient quality of life.
- Symptoms of FCS, such as abdominal pain and fatigue, are frequently misattributed to more common conditions, causing diagnostic delays.
Panelists discuss the importance of early diagnosis and treatment of Ffamilial Cchylomicronemia Ssyndrome (FCS), highlighting how misunderstood signs and symptoms often lead to delayed diagnosis, and explore the frequency of these delays in clinical practice.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you describe the importance of early diagnosis and treatment of FCS?
- Why are the signs and symptoms of FCS often misunderstood, leading to delayed diagnosis? How often does delayed diagnosis occur?
Advertisement
Related to this article
A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.
Volixibat reduced itch scores vs placebo in patients with PSC and moderate to severe pruritus in the phase 2b VISTAS trial presented at ACG 2026.
Topline phase 3 ALOFT-IPF data show admilparant 60 mg improved 52-week FVC vs placebo in IPF, while the 120 mg dose missed statistical significance.
Post hoc FORTIFY OLE analyses presented at ACG 2026 show sustained remission across disease locations and rising no-draining-fistula rates over 5 years.
Topline data show a 69% placebo-adjusted drop in serum bile acids, with an sNDA planned for the first half of 2027.
Jennifer Hsiao, MD, discusses HS treatment expectations, biologic selection, oral JAK inhibitors, and comorbidity screening.
Phase 3 extension shows oral denifanstat sustains acne lesion reductions through 52 weeks, with 57% IGA success and 77% fewer inflammatory lesions.
Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.
Advertisement
Advertisement
Trending on HCPLive
1
GLP-1 Initiation in Heart Failure Reduces Pulmonary Artery Pressure, Hospitalizations
2
Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD
3
Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism
4
ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point
5